Do You Need a Second Booster Shot?
People ages 50 years and older and certain immunocompromised individuals who are at higher risk for severe disease, hospitalization and ...
Long COVID Leaves Newly Disabled People Facing Old Barriers
Up to one-third of COVID-19 survivors will acquire the condition known as long or long-haul COVID-19.
How the ‘Test to Treat’ Initiative Aims to Get Ahead of the Next Wave of COVID-19
If a person tests positive and treatment is deemed appropriate, oral antiviral therapy can be prescribed on the spot at ...
Repurposing Generic Drugs can Reduce Time and Cost to Develop New Treatments
Most of the time when drugs are repurposed for diseases or conditions they were not originally intended for, it is ...
How the CDC and FDA Really Work
The CDC recently announced that it is evaluating its current organizational structure. We hope this leads to much needed changes, ...
A Comment on the CDC’s Commentary
For two months, the CDC allowed public comments on its draft revision of the opioid prescribing guidelines. They reveal that ...
Clinical Trial Meets Patient Advocacy
Clinical trials represent the science in healthcare. It is how we obtain new medical information. But to advance our knowledge ...
The cheerful lexicon of the Spanish language may help solve a health mystery called the Hispanic Paradox
This ability to minimize or exaggerate a situation by simply adding a suffix is one feature of the Spanish language ...
Why Black and Hispanic Seniors Are Left With a Less Powerful Flu Vaccine
“Since you have an increased risk of diabetes and heart disease in the African American community, it inherently disadvantages this ...
Failure to Include Black Communities in Health Policy Public Engagement Perpetuates Health Disparities
The fact that the communities with the worst health outcomes are also the communities least likely to be meaningfully engaged ...
Do We Really Know What a Million COVID-19 Deaths Mean?
For most people, visualizing what a million of anything looks like is an impossible task. The human brain just isn’t ...
Tomorrow’s COVID Safety Guidelines Will be Different From Today’s
The constant back and forth of rules can be frustrating, but policy changes aren’t usually a sign of mistakes. Rather, ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more